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ARTICLE

Acute Myeloid Leukemia

Comparison of total body irradiation versus
non-total body irradiation containing
regimens for de novo acute myeloid leukemia
in children
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ABSTRACT

W

ith limited data comparing hematopoietic cell transplant outcomes between myeloablative total body irradiation (TBI) containing and non-TBI regimens in children with de novo acute
myeloid leukemia, the aim of this study was to compare transplant-outcomes between these regimens. Cox regression models were used to compare transplant-outcomes after TBI and non-TBI regimens in 624 children
transplanted between 2008 and 2016. Thirty two percent (n=199) received
TBI regimens whereas 68% (n=425) received non-TBI regimens. Five-year
non-relapse mortality was higher with TBI regimens (22% vs. 11%,
P<0.0001) but relapse was lower (23% vs. 37%, P<0.0001) compared to
non-TBI regimens. Consequently, overall (62% vs. 60%, P=1.00) and
leukemia-free survival (55% vs. 52%, P=0.42) did not differ between treatment groups. Grade 2-3 acute graft versus host disease was higher with TBI
regimens (56% vs. 27%, P<0.0001) but not chronic graft versus host disease. The 3-year incidence of gonadal or growth hormone deficiency was
higher with TBI regimens (24% vs. 8%, P<0.001) but there were no differences in late pulmonary, cardiac or renal impairment. In the absence of a
survival advantage, the choice of TBI or non-TBI regimen merits careful
consideration with the data favoring non-TBI regimens to limit the burden
of morbidity associated with endocrine dysfunction.
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Introduction
Hematopoietic cell transplant (HCT) is accepted as the
standard of care for children and adolescents with high risk
or relapsed/refractory acute myeloid leukemia (AML).1-3
Total body irradiation (TBI) or busulfan (Bu) containing
myeloablative conditioning regimens are commonly used
to treat these patients.4,5 In 1992, a randomized trial in
adults showed improved 2-year leukemia-free survival
using conditioning with TBI-cyclophosphamide (Cy) compared to Bu-Cy using oral busulfan formulation, which was
available at that time,6 however, there are limited data in
children and adolescents. Intravenous Bu has subsequently
been developed, which provides more consistent pharmacokinetics and reliable dosing.7 Further, pharmacokinetic
targeting of intravenous Bu dosing reduces treatment-related toxicity.8 In the modern era, in adults, intravenous Buconditioning has been shown to be associated with
improved non-relapse mortality, and overall and diseasefree survival in comparison to TBI-containing regimens.9,10
However, acute graft versus host disease (GvHD),11 acute
liver injury,12 pulmonary injury (e.g., diffuse alveolar hemorrhage), and bloodstream infections1,13,14 are reported to be
higher with TBI-containing compared to non-TBI regimens.
Late complications, including secondary malignancies,
endocrine, metabolic, renal, ocular, and neurocognitive
complications are also higher with TBI-containing compared to non-TBI myeloablative regimens.15-17 Although
TBI-containing regimens are associated with significant
toxicity in children,18 many physicians continue to use TBIcontaining regimens for transplantation for de novo AML in
children and adolescents. In the absence of a randomized
trial comparing TBI-containing versus non-TBI regimens in
children, we utilized data on HCT reported to an observational registry, the Center for International Blood and
Marrow Transplant Research (CIBMTR) to compare outcomes between the two treatment groups.

cause was considered an event. Leukemia-free survival was
defined as being alive in continuous remission. Neutrophil recovery was defined as achieving a count of ≥0.5x109/L for 3 consecutive days. Platelet recovery was defined as achieving a count of
≥20x109/L without transfusions for 7 consecutive days. The day100 incidence of veno-occlusive disease, systemic bacterial, viral
and fungal infection were compared between the two treatment
groups. The 5-year incidence of post-transplant interstitial pneumonitis, congestive heart failure, gonadal dysfunction, growth
hormone deficiency and renal failure severe enough to warrant
dialysis were compared between the two treatment groups.

Statistical methods
Patient-related, disease-related, and transplant-related outcomes were compared between treatment groups using MannWhitney tests (continuous variables) and Fisher’s exact/Chisquare test (categorical variables). A P-value of <0.05 was considered statistically significant. Cox regression models were built for
acute and chronic GvHD, non-relapse mortality, relapse, overall
and leukemia-free survival.21 The main effect (TBI-containing vs.
non-TBI regimens) was forced in all models, and other covariates
were retained in the final model if they met a significance level of
less than 0.05. Forward stepwise selection was used to identify
significant covariates. The interaction between the main effect
and significant covariates was examined. Assessment of the proportional-hazards assumption was done by examining the coefficient of the logarithm of time from transplant to the last followup for each covariate. The coefficients for the covariates which
violated the proportional hazards assumption were added as
time-varying effects. The adjusted survival or cumulative incidence probabilities were calculated based on the final Cox models.22,23 Center effects were tested for non-relapse mortality,
relapse, overall and leukemia-free survival using the score test.24
All analyses were performed using SAS 9.4 (SAS Institute Inc,
Cary, NC).

Results
Methods
Patients
Data were reported prospectively to the CIBMTR, a voluntary
working group of more than 450 transplant centers worldwide
that contribute detailed data on allogeneic and autologous HCT.
Participating centers report consecutive transplants and compliance is monitored by on-site audits. All patients are followed
longitudinally until death or lost to follow-up. Eligible patients
were aged ≤21 years undergoing first allogeneic transplantation
with myeloablative conditioning for de novo AML in first or second complete remission between 2008 and 2016 and consented
for research. Excluded were patients with an antecedent hematologic disorder or secondary AML, mismatched related donor
transplant and non-calcineurin inhibitor GvHD prophylaxis regimens. Patients were broadly grouped into TBI-containing (TBICy), TBI-Cy-fludarabine (Flu) and non-TBI (Bu-Cy and Bu-Flu)
regimens. The study was approved by the Institutional Review
Board of the National Marrow Donor Program.

Endpoint
Grades 2-3 acute GvHD, grade 3-4 acute GvHD, and chronic
GvHD were defined using standard definitions.19,20 Relapse was
defined as the recurrence of AML (morphologic, cytogenetic or
molecular) and non-relapse mortality was defined as death in
remission. Overall survival was defined where death from any
1840

Patient, disease and transplant characteristics
Six hundred and twenty-four patients transplanted at
124 transplant centers were eligible and their characteristics are shown in Table 1. TBI-containing regimens included TBI-Cy (38%, 76 of 199) and TBI-Cy-Flu (62%, 123 of
199). Non-TBI regimens included Bu-Cy (76%, 322 of 425)
and Bu-Flu (24%, 103 of 425). Bu pharmacokinetics with
dose adjustments were performed for 80% (338 of 425) of
non-TBI transplantations. Patient and disease characteristics differed by treatment group. TBI-containing regimens
were less likely to be used for children aged 3 years and
younger, for transplants in first complete remission and
more likely with umbilical cord blood (67%). In very
young children (age ≤3 years, n=170), only 19% (33 of 170)
received a TBI regimen. Bone marrow was the predominant graft for non-TBI regimen transplants (48%). In vivo Tcell depletion with anti-thymocyte globulin was common
with non-TBI regimens accounting for 52% of transplantations compared to only 11% with TBI-containing regimens. The predominant GvHD prophylaxis with TBI-containing regimens was cyclosporine with mycophenolate
and for non-TBI regimen, tacrolimus or cyclosporine with
methotrexate. There were no differences between treatment groups regarding performance score, hematopoietic
co-morbidity index, sites at diagnosis and cytogenetic risk.
Most transplant centers used both TBI-containing and nonhaematologica | 2021; 106(7)
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TBI regimens (n=57) or non-TBI regimens alone (n=53).
Only 14 centers used TBI-containing regimens alone.
Further, between 2012 and 2016, only a third of transplants
used TBI-containing regimens. Non-TBI regimens were
equally likely to be used between 2008 and 2011 and
between 2012 and 2016. The median follow-up of patients
who received TBI-containing regimens was 63 months
(range, 3-122 months) and for those who received non-TBI
regimens, 50 months (range, 3–122 months).
Table 1. Patient, disease and transplant characteristics.

Variable
Sex
Male/female

TBI- regimens

Non-TBI regimens

101 (51%) /
98 (49%)

217 (51%) /
208 (49%)

P-value
0.94

Age
≤ 3 years
33 (17%)
4 – 10 years
49 (25%)
11 – 21 years
117 (59%)
Performance score
90 - 100
168 (84%)
≤ 80
26 (13%)
Not reported
5 ( 3%)
HCT co-morbidity index
≤2
172 (86%)
≥3
25 (13%)
Not reported
2 ( 1%)
Site(s) at diagnosis
Bone marrow only
132 (66%)
Bone marrow + central
52 (26%)
nervous system
Bone marrow + other sites
12 ( 6%)
Not reported
3 ( 2%)
Cytogenetic risk
Favorable
29 (15%)
Intermediate
123 (62%)
Poor
41 (21%)
Not reported
6 ( 3%)
Disease status at transplant
107 (54%)
1st complete remission
2nd complete remission
92 (46%)
Donor
HLA-matched sibling
17 ( 9%)
HLA-matched unrelated donor 34 (17%)
HLA-mismatched unrelated
14 ( 7%)
donor
HLA-matched unrelated
21 (11%)
cord blood
HLA-mismatched unrelated
101 (51%)
cord blood
Unrelated cord blood
12 ( 6%)
(not reported)
Graft versus host disease prophylaxis
Tacrolimus + mycophenolate
7 ( 4%)
Tacrolimus + methotrexate
40 (20%)
Tacrolimus alone`
4 ( 2%)
Cyclosporine + mycophenolate 119 (60%)
Cyclosporine + methotrexate
20 (10%)
Cyclosporine alone`
9 ( 5%)
Anti-thymocyte globulin
22 (11%)
Transplant period
2008 – 2011
133 (67%)
2012 – 2016
66 (33%)
TBI: total body irradiation; HCT: hematopoietic cell transplant.
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<0.001
137 (32%)
93 (22%)
195 (46%)
0.06
376 (88%)
47 (11%)
2 (<1%)
0.55
375 (88%)
43 (10%)
7 ( 2%)
0.14
295 (69%)
84 (20%)
29 ( 7%)
17 ( 4%)
0.14
36 ( 8%)
285 (67%)
90 (21%)
14 ( 3%)
277 (65%)
148 (35%)
123 (29%)
109 (26%)
32 ( 8%)
29 ( 7%)
99 (23%)
33 ( 8%)
<0.001

192 (45%)
233 (55%)

The median time to neutrophil recovery was 20 days and
17 days after TBI-containing and non-TBI regimens, respectively (P=0.04). The corresponding time to platelet recovery
were 38 days and 30 days, P=0.002. Consequently, the day28 incidence of neutrophil recovery was lower after TBIcontaining (79%, 95% Confidence Interval [CI]: 73–84)
compared to non-TBI regimens (85%, 95% CI: 82–88),
P=0.04. Similarly, day-100 incidence of platelet recovery
was also lower after TBI-containing (81%, 95% CI: 75–86)
compared to non-TBI regimens (87%, 95% CI: 84–90),
P=0.002.

Acute and chronic graft versus host disease
Grade 2-3 acute GvHD risk was higher with TBI-containing compared to non-TBI regimens (Table 2). The day-100
incidence of grade 2-3 acute GvHD were 56% (95% CI: 49–
63) and 27% (95% CI: 22–30), respectively, P<0.0001.
Compared to HLA-matched sibling donors, risks were
higher with HLA-matched unrelated (hazard ratio [HR]
3.03, 95% CI: 1.75–5.25, P<0.0001), HLA-mismatched
unrelated (HR 4.12, 95% CI: 2.18–7.77, P<0.0001), HLAmatched cord blood (HR 3.02, 95% CI: 1.44 –6.34,
P=0.0035) and HLA-mismatched cord blood (HR 2.95, 95%
CI: 1.57–5.56, P=0.0008). Grade 3-4 acute GvHD risk did
not differ between the treatment groups (Table 2).
Compared to bone marrow grafts, risk of acute GvHD was
higher with peripheral blood (HR 3.22, 95% CI: 1.72–6.03,
P=0.003) and cord blood (HR 2.24, 95% CI: 1.29–3.88,
P=0.0041). Chronic GvHD risk also did not differ between
treatment groups (Table 2). The 5-year incidence of chronic
GvHD was 37% (95% CI: 30– 44) and 30% (95% CI: 26–
35) after TBI-containing and non-TBI regimens. Chronic
GvHD risks were higher in patients aged 11–21 years compared to those aged ≤3 years (HR 1.78, 95% CI: 1,13–2.81,
Table 2. Results of multivariate analysis

0.006

42 (10%)
139 (33%)
8 ( 2%)
77 (18%)
115 (27%)
44 (10%
221 (52%)

Hematopoietic recovery

<0.001
<0.001

Outcome
Grade 2-4 acute GvHD*
TBI-containing regimen
Non-TBI regimen
Grade 3-4 acute GvHD
TBI-containing regimen
Non-TBI regimen
Chronic GvHD*
TBI-containing regimen
Non-TBI regimen
Non-relapse mortality║
TBI-containing regimen
Non-TBI regimen
Relapse#
TBI-containing regimen
Non-TBI regimen
Leukemia-free survival**
TBI-containing regimen
Non-TBI regimen
Overall survival║
TBI-containing regimen
Non-TBI regimen

P-value

Events/
Number

Hazard Ratio
(95% CI)

109/196
112/420

1.00
0.44 (0.33 – 0.58)

<0.0001

34/196
53/420

1.00
0.69 (0.44 – 1.08)

0.10

70/198
116/422

1.00
0.82 (0.59 – 1.13)

0.23

42/199
46/425

1.00
0.53 (0.35 – 0.81)

0.003

43/199
149/425

1.00
1.46 (1.04 – 2.07)

0.03

85/199
195/425

1.00
1.01 (0.78 – 1.31)

0.95

73/199
159/425

1.00
0.98 (0.74 – 1.30)

0.91

GvHD: graft versus host disease; TBI. total body irradiation: CI: Confidence Interval; TBI: total
body irradiation; *adjusted for age, donor type and GvHD prophylaxis; ║adjusted for age;
♯
adjusted for age and site(s) at diagnosis and **adjusted for age and cytogenetic risk.
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P=0.01) and 4–10 years (HR 2.29, 95% CI: 1.57–3.33,
P<0.0001). Chronic GvHD was higher with HLA-mismatched cord blood compared to HLA-matched sibling
donors (HR 2.04, 95% CI: 1.10–3.67, P=0.02). Chronic
GvHD risks did not differ between other donor groups
(data not shown).

Non-relapse mortality and relapse
Non-relapse mortality was higher with TBI-containing
regimens (Table 2, Figure 1A). The 1- and 5-year incidence
of non-relapse mortality with TBI-containing regimens
were 17% (95% CI: 12–22) and 22% (95% CI: 16–28). The
corresponding incidence with non-TBI regimens were 8%
(95% CI: 6–11) and 11% (95% CI: 8–15). Compared to
patients aged 4–10 years, non-relapse mortality was higher
in patients aged 11–21 years (HR 1.99, 95% CI: 1.15–3.46,
P=0.01) but not in those aged ≤3 years (HR 1.71, 95% CI:
0.85–3.44, P=0.13). Infections were higher with TBI-containing compared to non-TBI regimens (Table 3A). Venoocclusive disease was lower with TBI-containing regimens
(Table 3A). Patients who survived at least 1 year after transplantation in remission were evaluable for organ dysfunction (Table 3B). Endocrine dysfunction (thyroid or gonadal)
was higher with TBI-containing regimens. Pulmonary, cardiac and renal complications did not differ between treatment groups.
Relapse risks were lower in TBI-containing regimens
(Table 2, Figure 1B). The 1- and 5-year incidence of relapse
with TBI-containing regimens were 15% (95% CI: 11–22)
and 23% (95% CI: 17– 29). The corresponding relapse incidence with non-TBI regimens were 26% (95% CI: 22–31)
and 37% (95% CI: 32–42), P<0.0001. Relapse risks did not
differ between patients aged 4-10 and 11-21 years (HR 1.17,
95% CI: 0.82–1.69, P=0.39). Relapse was higher in patients
aged ≤3 years compared to those aged 4-10 years (HR 2.49,
95% CI: 1.68–3.69, P<0.0001) and 11–21 years (HR 2.12,
95% CI: 1.51–2.98, P<0.0001). Compared to bone marrow
and central nervous system involvement at diagnosis,

A

relapse risks were higher in patients with bone marrow
involvement alone (HR 1.93, 95% CI: 1.27–2.93, P=0.002)
and bone marrow with extramedullary site(s) excluding
central nervous system involvement (HR 1.88, 95% CI:
1.01–3.50, P=0.04). Acute grade 2-4 GvHD was associated
with lower relapse risk (HR 0.63, 95% CI: 0.44–0.89,
P=0.008) but this was independent of conditioning regimen. The effect of acute grade 3-4 (HR 0.65, 95% CI: 0.39–
1.09, P=0.10) and chronic GvHD (HR 0.74, 95% CI: 0.48–
1.15, P=0.19) on relapse did not meet the level of significance that was set a priori.

Overall and leukemia-free survival
There were no differences in overall or leukemia-free survival by treatment groups (Table 2, Figure 2A and B). Age
was associated with both overall and leukemia-free survival
and cytogenetic risk with leukemia-free survival.
Compared to patients aged 4-10 years, survival was lower
for those aged 11– 21 years (HR 1.82, 95% CI: 1.28–2.59,
P<0.0001) and ≤3 years (HR 2.79, 95% CI: 1.90–4.10,
P<0.0001). Survival was also lower in patients aged ≤3 years
compared to those aged 11–21 years (HR 1.52, 95% CI:
1.14–2.08, P=0.005). Compared to favorable cytogenetics,
leukemia-free survival was lower with intermediate risk
(HR 1.85, 95% CI: 1.10–3.09, P=0.0198) and poor risk (HR
2.46, 95% CI: 1.42–4.27, P=0.0013). The 5-year overall survival was 61% (95% CI: 54–68) and 61% (95% CI: 56–66)
after TBI-containing and non-TBI containing regimens. The
corresponding leukemia-free survival was 53% (95% CI:
46–60) and 53% (95% CI: 48–58).

Transplant period
As the current analysis included patients transplanted
between 2008 and 2016, we tested for an effect of transplant period (2012-2016 vs. 2008-2011) on non-relapse mortality (HR 0.75, 95% CI 0.48 - 21.17, P=0.21), relapse (HR
1.04, 95% CI: 0.78–1.41, P=0.78), overall (HR 0.93, 95% CI:
0.71– 1.22, P=0.62) and leukemia-free survival (HR 0.96,

B

Figure 1. Non-relapse mortality and relapse. (A) Cumulative incidence of non-relapse mortality with total body irradiation (TBI)-containing and non-TBI regimens, (B)
cumulative incidence of relapse with TBI-containing and non-TBI regimens.
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95% CI: 0.75–1.23, P=0.15) and found none. We also examined for differences in infection rates by transplant period
and observed lower rate of fungal infection between 2012
and 2016 compared to the earlier period in patients who
received TBI-containing (2% vs. 8%) and non-TBI (1% vs.
4%) regimens.

0.50–1.12, P=0.16), non-relapse mortality (HR 1.09, 95%
CI: 0.60–1.99, P=0.78), relapse (HR 1.07, 95% CI: 0.77–1.50,
P=0.68), overall (HR 1.24, 95% CI: 0.90–1.72, P=0.19) and
leukemia-free survival (HR 1.05, 95% CI: 0.78–1.40,
P=0.75) and found none.

Subset analysis

Discussion

In a subset analysis limited to patients who received BuCy and Bu-Flu, we examined for an effect of anti-thymocyte globulin on grade 2-4 acute GvHD (HR 0.68, 95% CI:
0.44–1.03, P=0.07), grade 3-4 acute GvHD (HR 0.93, 95%
CI: 0.51–1.70, P=0.82), chronic GvHD (HR 0.75, 95% CI:

To our knowledge this is the largest study to compare
TBI and non-TBI intravenous Bu containing regimens in
children and adolescents with de novo AML. Non-relapse
mortality was higher with TBI regimens, and relapse was

Table 3A. Day-100 incidence of veno-occlusive disease and systemic infection.

Outcome
VOD
Bacterial bloodstream infection
Viral bloodstream infection
Fungal bloodstream infection

N eval
197
199
199
199

TBI-containing regimen
Probability (95% CI)

N eval

8% (4-12)
47% (40-54)
43% (36-50)
6% (3-9)

422
425
425
425

Non-TBI regimen
Probability (95% CI)
15% (11-18)
30% (26-35)
30% (26-34)
2% (1-4)

P-value
0.03
<0.001
0.001
0.04

TBI: total body irradiation; VOD: veno-occlusive disease; CI: Confidence Interval; eval: evaluated.

Table 3B. 3-year incidence of organ dysfunction in patients who were alive and in remission for at least 1-year post-transplant

Outcome
Interstitial pneumonitis / Idiopathic
pneumonia syndrome
Endocrine dysfunction (gonadal
or growth hormone)
Cardiac failure, renal failure
requiring dialysis

N eval

TBI-containing regimen
Probability (95% CI)

N eval

Non-TBI regimen
Probability (95% CI)

P-value

129

5% (2-9)

267

7% (4-11)

0.36

125

24% (17-32)

265

8% (5-12)

<0.001

129

5% (2-9)

267

3% (1-5)

0.26

Number of events: gonadal dysfunction TBI n=28 of 125; non-TBI n=29 of 265; growth hormone deficiency TBI n=14 of 129, non-TBI n=7 of 265; cardiac failure TBI n=3 of 129,
non-TBI n=1 of 267; renal failure TBI n=4 of 129, non-TBI N=7 of 267. TBI: total body irradiation; CI: Confidence Interval; n: number; eval: evaluated.

A

B

Figure 2. Leukemia-free survival and overall survival. (A) Probability of overall survival with total body irradiation (TBI)-containing and non-TBI regimens, (B) probability of leukemia-free survival with TBI-containing and non-TBI regimens.
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higher with non-TBI regimens, negating an advantage for
overall or leukemia-free survival. The net contribution of
non-relapse mortality or relapse for either treatment
group was not sufficient to lead towards an overall or
leukemia-free survival advantage. Our findings are in
keeping with another pediatric study from Japan that also
failed to show differences in overall and leukemia-free
survival between TBI-containing and non-TBI Bu regimens.1 We hypothesize there are several factors that
influenced relapse risks including acute grade 2-4 GvHD.
TBI regimens were largely used with cord blood transplants and TBI-Cy-Flu was the predominant regimen.
Others have reported lower relapse with TBI-Cy-Flu regimen compared to other TBI- and non-TBI containing regimens for cord blood transplant.25 The higher incidence of
bacterial, viral and fungal infections with the TBI-containing regimens within the first 3 months after transplantation likely contributed to early transplant-related mortality. Whether this is an effect of the conditioning regimen
or the type of donor is challenging to differentiate as TBI
regimens were predominantly used for cord blood transplants. In the subset, limited to transplants between 2012
and 2016, the incidence of bacterial and viral infections
was also higher with TBI-regimens and consistent with
the main analysis. However, the incidence of invasive
fungal infection decreased to 2% with TBI regimens and
1% with non-TBI regimens for transplants between 2012
and 2016 (P=0.89) although this had negligible effect on
non-relapse mortality (HR 1.18, P=0.72). A higher 5-year
overall survival recorded with TBI-Cy-Flu compared to
non-TBI regimens may be acceptable for some considering cord blood transplant even though growth hormone
and gonadal deficiency is higher with TBI-Cy-Flu regimen.25 For transplantations with HLA-matched sibling or
adult unrelated donors intravenous Bu-Cy or Bu-Flu is
preferred.26,27 A recent study from the European Society
for Blood and Marrow Transplant (EBMT) observed
lower relapse and higher leukemia-free survival for AML
in first complete remission with Bu-Cy-melphalan compared to Bu-Cy and TBI-Cy.28 Our study did not include
the Bu-Cy-melphalan regimen.
Hematopoietic recovery was lower with TBI-containing
regimens. We hypothesize the lower recovery rates are in
part explained by the predominant use of umbilical cord
blood graft with TBI-containing regimens and in part, by use
of intravenous Bu for all patients and pharmacokinetic data
available for 80% of patients in the non-TBI group. Higher
neutrophil but not platelet recovery with intravenous Bu
containing regimens compared to TBI-containing regimens
has been reported in adults with acute leukemia.10
Consistent with other reports, TBI-containing regimens
were associated with higher incidence of thyroid and
growth hormone deficiency compared to non-TBI regimens.21,22 Although not studied in the current analysis, others have recorded higher risk of cataracts, neuropsychological and cognitive abnormalities with TBI-containing regimens.22-24 The 5-year incidence of cardiac failure and renal
failure were modest (<10%) but did not differ between
treatment groups. Although not the focus of the current
study, two recent publications studied the association
between myeloablative conditioning regimens and second
neoplasm. Those reports did not record a higher risk with
TBI-containing compared to non-TBI regimens.27,29
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There are limitations to studying the effect of transplant conditioning regimen in a retrospective cohort.
First, we do not know the factors that influenced choice
of conditioning regimen other than in the youngest age
group (≤3 years), approximately 70% of those who
received TBI regimen were in second complete remission.
Although we performed a carefully controlled analyses
there may be unknown or unmeasured factors that may
have influenced the outcomes recorded. Second, over the
course of the study, effective molecular flow cytometric
measures of detectable disease in patients in complete
remission at transplantation may have helped refine prognosis after transplantation30 although it can be argued that
the effect of minimal residual disease (MRD) would be
consistent across both treatment groups. Among 166
patients for whom MRD status was available, 6 of 33
(18%) patients who received TBI and 17 of 133 (13%)
patients who received non-TBI regimens were MRD negative at transplantation. Third, we know most patients
who received Bu had pharmacokinetic dose adjustments,
but we do not have data on dose adjustments to examine
whether an increase or decrease to the prescribed Bu dose
was associated with outcomes. Our study spanned a 9year period, a strength considering our sample size, but
leukemia-free and overall survival may be influenced by
transplant period. A careful analysis failed to find an
effect of transplant period on outcomes other than a
lower incidence of invasive fungal infection with TBI regimens.
Our findings are relevant regarding a discussion on the
choice of TBI-containing or non-TBI regimen when considering allogeneic transplantation for children and adolescents
with de novo AML. In the absence of a survival advantage
with either regimen group, the non-TBI regimens, Bu-Cy or
Flu-Bu, are preferred although when considering umbilical
cord blood transplantation TBI-Cy-Flu may be preferred.25
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